Cogent Biosciences

COGT

Market cap $6.03B

Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WALTHAM, Mass. and BOULDER, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2026 milestones ahead of its presentation at J.P. Morgan's 44th annual healthcare conference. “2025 was marked by exceptional progress at Cogent Biosciences,” said Andrew Robbins, President and Chief Executive Officer. “We reported positive results from all three pivotal trials of bezuclastinib in patients with GIST and Systemic Mastocytosis, submitted our first NDA for bezuclastinib in patients with NonAdvSM based on the strength of the SUMMIT data, and put ourselves in a very strong financial position entering the new year. During 2026, we will transform Cogent into a fully integrated commercial stage company with plans to launch bezuclastinib in the second half of the year. In addition, we are investing for the future and plan to submit INDs in 2026 for both our pan-KRAS inhibitor and recently announced JAK2 V617F inhibitor. Our plans are supported by a highly experienced team with proven launch experience backed by a strong balance sheet. We are poised for success and extremely excited about the meaningful impact we can have for patients.”  In 2026, Cogent plans to achieve the following milestones:

According to a Form 4, one Cogent Biosciences insider sold 65,000 shares of the biotech on Dec. 26 for a total value of $2.52 million. This sale represented 37.27% of Evan Kearns's direct holdings, as reported, reducing direct ownership to 109,398 shares.

WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET.

The biotech's chief legal and financial officers were among four executives who sold shares on the same day.

WALTHAM, Mass. and BOULDER, Colo.

Surprisingly, the Russell 2000 has a chance to be the second-best-performing index on the U.S. stock exchanges as we start to round out 2025, with the unprecedented push into small caps being inspired by the Fed's easing cycle.

Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript

-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients --

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.